View Clinical Trial (Medical Research Study)
Premature Coronary Artery Disease (CAD) in Severe Psoriasis
| City: |
|
Ann Arbor |
| State: |
|
Michigan |
| Zip Code: |
|
48109 |
| Conditions: |
|
Psoriasis - Coronary Artery Disease |
| Purpose: |
|
The purpose of this study is to compare the prevalence and severity of CAD (coronary artery
disease) in patients with and without severe psoriasis, otherwise matched for cardiovascular
risk factors.
|
| Study Summary: |
|
To establish the relationship between psoriasis and coronary disease by comparing the
prevalence and severity of CAD (coronary artery disease) in patients with and without severe
psoriasis, otherwise matched for cardiovascular risk factors, as determined by CT coronary
calcium scoring and Coronary CT angiography.
|
| Criteria: |
|
Inclusion Criteria:
1. Patients with severe psoriasis as determined by more than two episodes of systemic or
inpatient treatment and 10% or more body surface area involvement.
2. Male or female ages 18 to 55 (because CAD risk has been shown to be greatest in
younger psoriasis patients in earlier studies, this pilot study will focus on young
individuals).
3. Able to give informed consent
Exclusion Criteria:
1. Prior diagnosis of CAD or heart disease based upon one or more of the following:
- coronary arteriography
- percutaneous coronary intervention
- cardiac surgery including bypass graft surgery
- valve surgery
- congenital heart disease repair
- stress ECG or imaging
- myocardial infarction
- angina or unstable angina
- congestive heart failure
- cardiomyopathy
2. History of anti-oxidants such as fish oil or biologic therapy Tumor Necrosis Factor
alpha inhibitors (such as etanercept, adalimumab, or infliximab). A recent review by
Sattar et al [22] has shown preliminary evidence that TNF blockade can modulate
nontraditional cardiovascular risk factors such as C-reactive protein(CRP),
Interleukin-6(IL-6), Apolipoprotein AI(ApoAI), Lipoprotein(a)(Lp[a]), Sex Hormone
Binding Globulin (SHBG), and homocysteine to exert a possible vascular and metabolic
protective effect.
3. Pustular and erythrogenic psoriasis
4. Unable to give informed consent
5. Contraindications to coronary CT, including:
- Irregular heart rate, such as multiple PVCs, atrial fibrillation
- Active heart failure
- Serum creatinine > 1.5mg/dl
- Weight > 320 lbs (due to degradation in CT image quality by image noise)
- History of severe allergy to intravenous contrast media
- High irregular heart rate with contraindications to beta-blockers
- Pregnant
|
| NCT ID: |
|
NCT00893126 |
| Primary Contact: |
|
Principal Investigator
Prachi P Agarwal, M.D.
University of Michigan Hospital
Prachi P Agarwal, M.D.
Phone: 734-936-4366
Email: prachi@umich.edu
|
| Backup Contact: |
|
N/A |
| Location Contact: |
|
Ann Arbor, Michigan 48109
United States
Prachi P Agarwal, M.D.
Phone: 734-936-4366
Email: prachi@umich.edu
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 20, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|